103 related articles for article (PubMed ID: 25196490)
1. Influence of smoking dosage and chronic obstructive lung disease on the incidence of appropriate therapies and mortality in patients with structural heart disease and an implantable cardioverter defibrillator.
Kreuz J; Skowasch D; Kamrath P; Lorenzen H; Tiyerili V; Linhart M; Nickenig G; Schwab JO
Pacing Clin Electrophysiol; 2015 Jan; 38(1):71-6. PubMed ID: 25196490
[TBL] [Abstract][Full Text] [Related]
2. Cigarette smoking and the risk of supraventricular and ventricular tachyarrhythmias in high-risk cardiac patients with implantable cardioverter defibrillators.
Goldenberg I; Moss AJ; McNitt S; Zareba W; Daubert JP; Hall WJ; Andrews ML;
J Cardiovasc Electrophysiol; 2006 Sep; 17(9):931-6. PubMed ID: 16759297
[TBL] [Abstract][Full Text] [Related]
3. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
[TBL] [Abstract][Full Text] [Related]
4. Clinical prediction model for death prior to appropriate therapy in primary prevention implantable cardioverter defibrillator patients with ischaemic heart disease: the FADES risk score.
van Rees JB; Borleffs CJ; van Welsenes GH; van der Velde ET; Bax JJ; van Erven L; Putter H; van der Bom JG; Schalij MJ
Heart; 2012 Jun; 98(11):872-7. PubMed ID: 22581736
[TBL] [Abstract][Full Text] [Related]
5. Smokers are at markedly increased risk of appropriate defibrillator shocks in a primary prevention population.
Sánchez JM; Greenberg SL; Chen J; Gleva MJ; Lindsay BD; Smith TW; Faddis MN
Heart Rhythm; 2006 Apr; 3(4):443-9. PubMed ID: 16567292
[TBL] [Abstract][Full Text] [Related]
6. Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure treated with combined cardiac resynchronization plus implantable cardioverter-defibrillator therapy versus implantable cardioverter-defibrillator therapy.
Desai H; Aronow WS; Ahn C; Tsai FS; Lai HM; Gandhi K; Amin H; Frishman WH; Kalapatapu K; Cohen M; Sorbera C
J Cardiovasc Pharmacol Ther; 2010 Mar; 15(1):37-40. PubMed ID: 19966176
[TBL] [Abstract][Full Text] [Related]
7. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study.
Koller MT; Schaer B; Wolbers M; Sticherling C; Bucher HC; Osswald S
Circulation; 2008 Apr; 117(15):1918-26. PubMed ID: 18391108
[TBL] [Abstract][Full Text] [Related]
8. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
[TBL] [Abstract][Full Text] [Related]
9. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention.
Bhonsale A; James CA; Tichnell C; Murray B; Gagarin D; Philips B; Dalal D; Tedford R; Russell SD; Abraham T; Tandri H; Judge DP; Calkins H
J Am Coll Cardiol; 2011 Sep; 58(14):1485-96. PubMed ID: 21939834
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of sleep-disordered breathing to predict occurrence of appropriate and inappropriate implantable-cardioverter defibrillator therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death.
Kreuz J; Skowasch D; Horlbeck F; Atzinger C; Schrickel JW; Lorenzen H; Nickenig G; Schwab JO
Am J Cardiol; 2013 May; 111(9):1319-23. PubMed ID: 23411108
[TBL] [Abstract][Full Text] [Related]
11. The impact of co-morbidity burden on appropriate implantable cardioverter defibrillator therapy and all-cause mortality: insight from Danish nationwide clinical registers.
Ruwald AC; Vinther M; Gislason GH; Johansen JB; Nielsen JC; Petersen HH; Riahi S; Jons C
Eur J Heart Fail; 2017 Mar; 19(3):377-386. PubMed ID: 27905161
[TBL] [Abstract][Full Text] [Related]
12. The gender-paradox among patients with implantable cardioverter-defibrillators: a propensity-matched study.
Bhavnani SP; Pavuluri V; Coleman CI; Guertin D; Yarlagadda RK; Clyne CA; Kluger J
Pacing Clin Electrophysiol; 2013 Jul; 36(7):878-84. PubMed ID: 23614760
[TBL] [Abstract][Full Text] [Related]
13. Ventricular arrhythmias among implantable cardioverter-defibrillator recipients for primary prevention: impact of chronic total coronary occlusion (VACTO Primary Study).
Nombela-Franco L; Mitroi CD; Fernández-Lozano I; García-Touchard A; Toquero J; Castro-Urda V; Fernández-Diaz JA; Perez-Pereira E; Beltrán-Correas P; Segovia J; Werner GS; Javier G; Luis AP
Circ Arrhythm Electrophysiol; 2012 Feb; 5(1):147-54. PubMed ID: 22205684
[TBL] [Abstract][Full Text] [Related]
14. Left ventricular function improvement after prophylactic implantable cardioverter-defibrillator implantation in patients with non-ischaemic dilated cardiomyopathy.
Grimm W; Timmesfeld N; Efimova E
Europace; 2013 Nov; 15(11):1594-600. PubMed ID: 23639855
[TBL] [Abstract][Full Text] [Related]
15. Ventricular tachyarrhythmias and mortality in patients with an implantable cardioverter defibrillator: impact of depression in the MIDAS cohort.
Mastenbroek MH; Versteeg H; Jordaens L; Theuns DA; Pedersen SS
Psychosom Med; 2014 Jan; 76(1):58-65. PubMed ID: 24336430
[TBL] [Abstract][Full Text] [Related]
16. Implantable cardioverter-defibrillators in patients with COPD.
Naksuk N; Kunisaki KM; Benditt DG; Tholakanahalli V; Adabag S
Chest; 2013 Sep; 144(3):778-783. PubMed ID: 23681102
[TBL] [Abstract][Full Text] [Related]
17. Pre-implantation implantable cardioverter defibrillator concerns and Type D personality increase the risk of mortality in patients with an implantable cardioverter defibrillator.
Pedersen SS; van den Broek KC; Erdman RA; Jordaens L; Theuns DA
Europace; 2010 Oct; 12(10):1446-52. PubMed ID: 20719779
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in chagas' heart disease.
Martinelli M; de Siqueira SF; Sternick EB; Rassi A; Costa R; Ramires JA; Kalil Filho R
Am J Cardiol; 2012 Oct; 110(7):1040-5. PubMed ID: 22727179
[TBL] [Abstract][Full Text] [Related]
19. Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT.
Sood N; Ruwald AC; Solomon S; Daubert JP; McNitt S; Polonsky B; Jons C; Clyne CA; Zareba W; Moss AJ
Eur Heart J; 2014 Jan; 35(2):106-15. PubMed ID: 24179073
[TBL] [Abstract][Full Text] [Related]
20. Outcomes in patients with sustained ventricular tachyarrhythmias occurring within 48 h of acute myocardial infarction: when is ICD appropriate?
Liang JJ; Hodge DO; Mehta RA; Russo AM; Prasad A; Cha YM
Europace; 2014 Dec; 16(12):1759-66. PubMed ID: 25100756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
